Raymond James Financial, Inc. upgraded shares of Juno Therapeutics, Inc. (NASDAQ:JUNO) from a market perform rating to an outperform rating in a research report sent to investors on Tuesday morning. Raymond James Financial, Inc. currently has $45.00 price objective on the biopharmaceutical company’s stock.

A number of other equities analysts have also recently commented on the stock. Vetr raised shares of Juno Therapeutics to a buy rating in a research report on Tuesday, May 23rd. Wedbush reaffirmed a neutral rating and set a $24.00 price objective on shares of Juno Therapeutics in a research report on Friday, May 5th. BidaskClub raised shares of Juno Therapeutics from a buy rating to a strong-buy rating in a research report on Tuesday, June 27th. Morgan Stanley reduced their price objective on shares of Juno Therapeutics from $27.00 to $26.00 and set an equal weight rating for the company in a research report on Monday, May 8th. Finally, FBR & Co reaffirmed a hold rating on shares of Juno Therapeutics in a research report on Thursday, May 18th. Two analysts have rated the stock with a sell rating, six have issued a hold rating and eight have issued a buy rating to the stock. The company has a consensus rating of Hold and a consensus target price of $31.86.

Juno Therapeutics (NASDAQ JUNO) opened at 43.81 on Tuesday. The stock’s market cap is $4.60 billion. Juno Therapeutics has a 52 week low of $17.52 and a 52 week high of $44.60. The stock has a 50 day moving average of $28.62 and a 200-day moving average of $25.14. Juno Therapeutics also was the recipient of unusually large options trading activity on Tuesday. Stock traders bought 6,838 put options on the company. This is an increase of 977% compared to the typical volume of 635 put options.

Juno Therapeutics (NASDAQ:JUNO) last released its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.96) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.72) by $0.24. Juno Therapeutics had a negative return on equity of 27.10% and a negative net margin of 354.36%. The company had revenue of $21.30 million for the quarter, compared to the consensus estimate of $15.59 million. During the same period last year, the firm earned ($0.64) earnings per share. The company’s revenue for the quarter was down 22.8% compared to the same quarter last year. Analysts forecast that Juno Therapeutics will post ($3.12) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Juno Therapeutics, Inc. (JUNO) Upgraded to Outperform by Raymond James Financial, Inc.” was first published by Watch List News and is owned by of Watch List News. If you are accessing this news story on another site, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this news story can be viewed at https://www.watchlistnews.com/juno-therapeutics-inc-juno-upgraded-to-outperform-by-raymond-james-financial-inc/1531454.html.

In other Juno Therapeutics news, Director Anthony B. Evnin bought 9,000 shares of Juno Therapeutics stock in a transaction dated Tuesday, June 20th. The stock was bought at an average price of $24.40 per share, with a total value of $219,600.00. Following the completion of the transaction, the director now owns 66,301 shares in the company, valued at approximately $1,617,744.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Steve Harr sold 8,750 shares of the business’s stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $30.00, for a total transaction of $262,500.00. Following the completion of the sale, the chief financial officer now directly owns 736,189 shares of the company’s stock, valued at approximately $22,085,670. The disclosure for this sale can be found here. In the last three months, insiders sold 8,053,500 shares of company stock valued at $217,594,440. 15.26% of the stock is currently owned by company insiders.

Several large investors have recently made changes to their positions in JUNO. Baillie Gifford & Co. boosted its stake in shares of Juno Therapeutics by 1.2% in the first quarter. Baillie Gifford & Co. now owns 11,197,863 shares of the biopharmaceutical company’s stock worth $248,481,000 after buying an additional 135,908 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Juno Therapeutics by 2.1% in the second quarter. Vanguard Group Inc. now owns 6,285,676 shares of the biopharmaceutical company’s stock worth $187,879,000 after buying an additional 131,864 shares during the last quarter. BlackRock Inc. increased its position in Juno Therapeutics by 2.6% in the second quarter. BlackRock Inc. now owns 4,294,296 shares of the biopharmaceutical company’s stock worth $128,357,000 after buying an additional 110,503 shares during the period. State Street Corp increased its position in Juno Therapeutics by 7.4% in the second quarter. State Street Corp now owns 3,236,384 shares of the biopharmaceutical company’s stock worth $96,742,000 after buying an additional 222,754 shares during the period. Finally, Capital World Investors increased its position in Juno Therapeutics by 13.8% in the second quarter. Capital World Investors now owns 2,425,000 shares of the biopharmaceutical company’s stock worth $72,483,000 after buying an additional 295,000 shares during the period. 70.76% of the stock is owned by institutional investors.

Juno Therapeutics Company Profile

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Analyst Recommendations for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.